Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Carotid Atherosclerosis: early-phase trial registry

2 of 6 indexed Carotid Atherosclerosis trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 2 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Carotid Atherosclerosis: 6 US clinical trials tracked, 2 recruiting.

Carotid Atherosclerosis is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Washington University School of Medicine, running 3 of these trials.

Enrollment posture brief

Registry condition carotid-atherosclerosis

OPEN 2 | RECR 33% | LATE 1 | EARLY 3 | RANK #2866 | SPON 3

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%Carotid Atherosclerosis (thi…33%
Open-enrollment share among volume-matched conditions near Carotid Atherosclerosis

Carotid Atherosclerosis lists 2 open slots (33% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Carotid Atherosclerosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Carotid Atherosclerosis is recruiting below its size-band peers.

    2 of 6 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Carotid Atherosclerosis research.

    Washington University School of Medicine accounts for 3 of 6 trials (50%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Typical Carotid Atherosclerosis enrolment sits around 100 participants.

    Median target enrolment is 100 among the 6 trials that report a genuine target (sentinel values excluded). 3 of those (50%) plan for fewer than 100 participants.

  4. Carotid Atherosclerosis splits between interventional and observational designs.

    4 interventional and 2 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 41

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 4 1

Named interventions

Most-linked intervention names on Carotid Atherosclerosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cu[64]-25%-CANF-Comb PET-MR Device
1 trials
cytokine and leukocyte activation profile Procedure
1 trials
Perflutren Diagnostic test
1 trials
Group 2 64CU-DOTA-ECL1i (radioactive imaging medicine) Drug
1 trials
Group 1-64CU-DOTA-ECL1i (radioactive imaging medicine) Drug
1 trials
64Cu-25%-CANF-Comb Drug
1 trials

US sites by state

Facility locations filed on Carotid Atherosclerosis trials. A trial with sites in several states counts in each.

Missouri 3 trials
Maryland 2 trials
Pennsylvania 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Carotid Atherosclerosis page

6 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Carotid Atherosclerosis condition card totals 6 registered trials; most-linked intervention Cu[64]-25%-CANF-Comb PET-MR; top US site state Missouri. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.